Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
212Pb-PSMA
- Development stage
- Preclinical
- Lead developer
- Orano Med
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Beta-minus Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
212Pb-PSMA is a targeted alpha therapy (TAT) radiopharmaceutical developed by Orano Med for the treatment of prostate cancer. It comprises a peptide ligand designed to bind with high affinity to the prostate-specific membrane antigen (PSMA), a protein significantly overexpressed on the surface of prostate cancer cells. The peptide is conjugated to lead-212 (212Pb), a radioisotope that acts as an in vivo generator of alpha particles. Upon binding to PSMA and subsequent internalization into the cancer cell, the decay of 212Pb releases high-energy alpha radiation. This radiation causes complex, difficult-to-repair double-strand DNA breaks, leading to cell death. This targeted approach is intended to maximize therapeutic efficacy against tumor cells while minimizing exposure and damage to surrounding healthy tissues.
- Other names
- Lead-212-PSMALead212-PSMALead 212-PSMA212Pb-labeled PSMA-targeting peptide
02
Targets
PSMA (Prostate-specific membrane antigen)DNA
Beyond the preview
Go deeper on 212Pb-PSMA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 212Pb-PSMA.